Status:
COMPLETED
Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation
Lead Sponsor:
Jie Chen
Conditions:
Nausea and Vomiting
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
This study aims to determine the role of Glycopyrrolate in preventing postoperative nausea and vomiting of ERCP.
Detailed Description
This study is a prospective, double-blind, randomized controlled trial. Patients who meet the criteria of our center and need to undergo ERCP lesion resection will be included and randomly divided int...
Eligibility Criteria
Inclusion
- Adults 18-80 years old 2.ASA :I-III 3.Patients who are able to give informed consent and are currently planning to have the lesion removed or examined at the descending ERCP
Exclusion
- 1: Use of anticholinergic drugs
- 2: pregnancy
- 3: glaucoma
- 4: Myasthenia gravis
- 5: Obstructive gastrointestinal diseases
- 6: Obstructive urinary tract disease (prostatic hyperplasia)
- 7: Heart disease (coronary heart disease, congestive heart failure)
- 8: hyperthyroidism
- 9: Previous history of abdominal or intestinal surgery
- 10: Chronic renal failure
- \-
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT06045364
Start Date
October 1 2023
End Date
July 31 2024
Last Update
September 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital Of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400000